Today: 29 June 2026
Browse Category

NASDAQ:TTRX 9 October 2025

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics shares surged to around $23 midday Oct. 9 after opening at $24.50, following a prior close of $7. Market cap jumped to over $500 million from under $100 million. The stock debuted on Nasdaq Oct. 8 via direct listing and has traded with extreme volatility, more than tripling in value amid speculative interest. No new FDA approvals were announced this week.
9 October 2025
··

Stock Market Today

  • IBM Removed from Russell 1000 Defensive Index
    June 29, 2026, 12:15 AM EDT. International Business Machines Corporation (NYSE: IBM) has been dropped from the Russell 1000 Defensive Index. The index tracks U.S. large-cap stocks with lower volatility and defensive characteristics, typically shielding investors during market downturns. IBM's removal could reflect shifts in its market profile or volatility. This change is part of the annual reconstitution process of the Russell indices, which adjusts components based on updated market data and criteria.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop